Management of Localized Non-Small Cell Lung Cancer with EGFR Tumor Mutations with Dr Roy Herbst

Episode 70 · April 12th, 2021 · 39 mins 1 sec

About this Episode

Dr Roy Herbst from the Yale Cancer Center discusses the clinical data on and optimal use of adjuvant osimertinib for patients with resected non-small cell lung cancer and an EGFR mutation.

CME information and select publications here.